PPARG and attention deficit-hyperactivity disorder: To this end, we tested whether the PPARγ agonist pioglitazone can activate mitochondrial biogenesis and/or antioxidant pathways in various brain regions of neonatal rats lesioned unilaterally by striatal 6-OHDA injection, and thereby reduce ADHD-like behavioral phenotypes.